"N-Myc Proto-Oncogene Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A basic helix-loop-helix leucine zipper (bHLHZ) transcription factor and proto-oncogene protein that functions in cell growth and proliferation. In mammals, it is highly expressed in the brain during embryogenesis and is essential for brain development; it is not expressed in adult tissues. Amplification or overexpression of N-Myc occurs in at least 20% of tumors and is associated with a poor prognosis in cases of NEUROBLASTOMA; ALVEOLAR RHABDOMYOSARCOMA; SMALL CELL LUNG CARCINOMA; and neuroendocrine prostate cancer.
Descriptor ID |
D000071447
|
MeSH Number(s) |
D12.776.260.103.500.625 D12.776.260.108.092.625 D12.776.624.664.700.158 D12.776.930.125.500.563 D12.776.930.127.092.625
|
Concept/Terms |
N-Myc Proto-Oncogene Protein- N-Myc Proto-Oncogene Protein
- N Myc Proto Oncogene Protein
- Proto-Oncogene Protein, N-Myc
- BHLHE37 Protein
- NMYC Protein
- Class E Basic Helix-Loop-Helix Protein 37
- Class E Basic Helix Loop Helix Protein 37
- N-Myc Protein
- N Myc Protein
- MYCN Protein
|
Below are MeSH descriptors whose meaning is more general than "N-Myc Proto-Oncogene Protein".
Below are MeSH descriptors whose meaning is more specific than "N-Myc Proto-Oncogene Protein".
This graph shows the total number of publications written about "N-Myc Proto-Oncogene Protein" by people in this website by year, and whether "N-Myc Proto-Oncogene Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2012 | 0 | 2 | 2 |
2015 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "N-Myc Proto-Oncogene Protein" by people in Profiles.
-
CoNCoS: copy number estimation in cancer with controlled support. J Bioinform Comput Biol. 2015 Oct; 13(5):1550027.
-
Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors. Oncotarget. 2015 Jun 20; 6(17):15425-35.
-
Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome. Br J Cancer. 2012 Oct 09; 107(8):1409-17.
-
Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. Int J Cancer. 2013 Feb 01; 132(3):E106-15.